ArticleScientific reports2025
Validation of the age, neutrophil to lymphocyte ratio, C reactive protein score on 28 day mortality in the National COVID cohort collaborative.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association between clinical symptoms and time to pharyngeal PCR negativity among mild omicron COVID-19 patients: a retrospective study.BMC infectious diseases · 2026Article
- Albumin-Anchored Composite Ratios of Blood Urea Nitrogen, C-Reactive Protein, Lactate, and Creatinine for Predicting Mortality in Chronically Ill Intensive Care Unit Patients.Journal of clinical medicine · 2026Article
- Prognostic Factors and Clinical Prediction Score for Progressive Respiratory Failure in Severe COVID-19 Pneumonia Patients Treated with Tocilizumab: A Multicenter Study.Therapeutics and clinical risk management · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Identifying patients at high mortality risk can improve outcomes in SARS-CoV-2 pneumonia (COVID-19). We validate a prognostic model for mortality in patients hospitalized with COVID-19 receiving dexamethasone using a retrospective multi-centered study. This is a retrospective cohort study using the National COVID Cohort Collaborative (NC3) including 9,708 adult patients admitted for COVID-19 who received dexamethasone within 24 h of admission and remained hospitalized for 72 h. Previous work from a single-center cohort informed selection of prognostic variables including Age, day 3 neutrophil-lymphocyte Ratio, and day 3 C-reactive protein level (ARC Score). Variables from the development cohort were analyzed in a training cohort, and the resulting model was tested in a validation cohort. Age and day 3 measures of the neutrophil-lymphocyte ratio and C-reactive protein level were included in a logistic regression model to predict 28-day mortality. The 28-day mortality in this patient population was 15.4%. The area under the curve for the ARC model was 0.77 (95% confidence interval, 0.74-0.79). The Age, neutrophil-lymphocyte Ratio, and C-reactive protein (ARC) score identifies COVID-19 patients with a high risk of mortality within 28 days of hospitalization using clinical information on day 3 of hospitalization. ARC scores perform well across all variants of concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.